NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ambagon Therapeutics

Ambagon Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.ambagontx.com/

Last Round

Series A

Jan 6, 2022

Total Funding Raised

$103M

Company Overview

Ambagon Therapeutics is a biotechnology company that develops small-molecule cancer drugs by stabilizing the interaction of 14-3-3 proteins with oncogenic client proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular gluedrug discoveryprotein-protein interactionsundruggable targetstargeted protein degradationTPDoncology researchstructural biologybiotech partnerships14-3-3 proteinscomputational drug discoveryprotein stabilizationdrug discovery platformpre-clinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ambagon Therapeutics Comparables

Compare Ambagon Therapeutics with similar companies based on industry and business-model similarity.

Ambagon Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Magnet Biomedicine
92%
Plexium
89%
SEED Therapeutics
88%

Ambagon Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 6, 2022
SeedJul 1, 2020

Key People

Founding team and executive leadership

Christian Ottmann

Chief Technology Officer

Executive Team

Ambagon Therapeutics Investors

Notable investors and investment history

Ambagon Therapeutics investors
InvestorRounds
Surveyor CapitalSeries A
RA Capital ManagementSeries A, Seed
Droia VenturesSeed, Series A
BioInnovation CapitalSeries A
AbbVie VenturesSeed, Series A
CitadelSeries A
Inkef CapitalSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 6, 2022

    $85M round led by Nextech Invest.

  • Jul 1, 2020

    $18M round led by RA Capital Management.

Ambagon Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ambagon Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ambagon Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range16
Year Founded2020
Last FundingJan 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.